YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.06 HKD | -1.09% |
|
-0.44% | -4.53% |
| May. 16 | YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Proposes Special Dividend | CI |
| May. 08 | Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma | MT |
| Sales 2024 * | 6.65B 917M 7.16B | Sales 2025 * | 6.82B 941M 7.35B | Capitalization | 7.49B 1.03B 8.06B |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 1.1 x |
| Net cash position 2024 * | 161M 22.25M 174M | Net cash position 2025 * | 918M 127M 989M | EV / Sales 2025 * | 0.96 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
11.8% | Yield 2025 * |
12% | Free-Float | 27.7% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.09% | ||
| 1 week | -0.44% | ||
| Current month | -8.48% | ||
| 1 month | -19.54% | ||
| 3 months | -13.88% | ||
| 6 months | -3.31% | ||
| Current year | -4.53% |
1 week
8.87
9.37
1 month
8.8711.20
Current year
7.9113.30
1 year
6.0213.30
3 years
3.3513.30
5 years
3.3527.23
10 years
3.3527.23
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Cai Jiang
CEO | Chief Executive Officer | 42 | 15-05-03 |
Qiang Zhang
DFI | Director of Finance/CFO | 49 | 18-02-22 |
Hao Chen
BRD | Director/Board Member | 49 | 09-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xin Fa Tang
CHM | Chairman | 54 | 15-05-03 |
Jun Cai Jiang
CEO | Chief Executive Officer | 42 | 15-05-03 |
Dan Jin Wang
BRD | Director/Board Member | 54 | 06-02-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.22% | 4 M€ | -27.92% | ||
| 0.00% | 32 M€ | +3.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-17 | 9.06 | -1.09% | 1 584 800 |
| 24-06-14 | 9.16 | +0.11% | 1,038,200 |
| 24-06-13 | 9.15 | +0.33% | 1,363,000 |
| 24-06-12 | 9.12 | +0.22% | 928,200 |
| 24-06-11 | 9.1 | -3.19% | 2,687,400 |
Delayed Quote Hong Kong S.E., June 17, 2024 at 04:08 am EDT
More quotes
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of pharmaceutical products. The Company is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.508
CNY
Average target price
14.33
CNY
Spread / Average Target
+68.47%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.53% | 1.03B | |
| +50.70% | 791B | |
| +41.48% | 630B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +17.45% | 246B | |
| +0.16% | 225B | |
| +10.19% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
- Stock Market
- Equities
- 1558 Stock
